Concord Biotech IPO Review | Issue Details, Service Portfolio, And More

Описание: The initial public offering (IPO) of Concord Biotech Limited has opened for subscribers and it will remain open for bidders till 8th August 2023. The public issue aims to raise ₹1,551 crore and the book build issue is completely offer for sale (OFS) in nature.

Concord Biotech’s Issue details:

Opens on: 4th Aug
Closes on: 8th Aug
Issue size: Rs. 1,551 crore
Price band: Rs. 705-741 per share
Lot size: 20 shares

Source: Concord Biotech’s RHP

Tune in to know more about the company, IPO issue details, future strategies, important financial details, presence, reach service portfolio, and much more with Kinjal Parekh!

#KotakSecurities #IPOReview #NewIPO #IPO #ConcordBiotech #ConcordBiotechIPO

Kotak Securities is a preferred choice of millions of customers when it comes to investment decisions. With free access to credible research, competitive pricing, and high-speed trading platforms, it makes investing an effortless journey for both new investors and experienced traders. To open a FREE Demat and trading account with Kotak Securities, please click here: https://www.kotaksecurities.com/

Disclaimer: https://bit.ly/KSLResearchDisclaimer
-----------------------------------------------------------------------------------------------
To watch more videos on Stock Updates,
▶️ Subscribe to Kotak Securities & hit the 🔔 to watch our videos first. ​
🌐 LEARN MORE ABOUT STOCKS: https://www.kotaksecurities.com/

------------------------------------------------------------------------------------------
FOLLOW US FOR STOCK UPDATES ON:
Telegram - https://t.me/KotakSecurities
Twitter:   / kotaksecurities  
Instagram:   / kotaksecurities  
LinkedIn:   / kotak-securities  
Facebook:   / kotaksecurities  
------------------------------------------------------------------------------------------
Customer Service: 1800 209 9191

We hope you enjoy your investment experience with us. If you have any other questions, please feel free to email our support team.